{
    "clinical_study": {
        "@rank": "3176", 
        "acronym": "BREAK-DHF-1", 
        "arm_group": {
            "arm_group_label": "Alagebrium", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to gather information regarding the safety and effectiveness of\n      an investigational drug called Alagebrium when used treating Heart Failure in relation to\n      exercise tolerance after 6 months in the trial."
        }, 
        "brief_title": "A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure", 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": "Diastolic Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Heart Failure, Diastolic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females 50 years of age or older.\n\n          2. Diagnosis of diabetes OR a diagnosis of hypertension requiring therapy.\n\n          3. Echocardiographic ejection fraction \u2265 45% verified within 1 year prior to baseline,\n             assuming no intercurrent cardiac event between the echo and screening.\n\n          4. Echocardiographic evidence of diastolic dysfunction as defined by an E/E' \u2265 12\n             determined within 1 year prior to baseline; sinus rhythm required at time of echo.\n\n          5. Previous hospitalization due to heart failure OR a current or previous BNP \u2265 100\n             pg/mL.\n\n          6. New York Heart Association (NYHA) functional class II-IV.\n\n          7. At least 1 month between hospitalization for heart failure and randomization.\n\n          8. Stable doses of heart failure medications (diuretics, ACE inhibitors, ARB's,\n             beta-adrenergic antagonists, aldosterone antagonists) for at least 1 month prior to\n             randomization.\n\n          9. Able to understand content of and willing to provide written informed consent.\n\n         10. Agree to use adequate contraception during the study if premenopausal. -\n\n        Exclusion Criteria:\n\n          1. Ejection fraction < 45%.\n\n          2. Screening Six-minute walk test > 450 meters or < 100 meters\n\n          3. Clinically significant cardiac valvular disease (mitral regurgitation (MR) > grade I,\n             aortic insufficiency (AI) > grade 1, mitral stenosis (MS), aortic stenosis (AS)).\n\n          4. History of stroke, any sequelae of a transient ischemic attack (TIA), or reversible\n             ischemic neurological defect (RIND) within 6 months prior to screening.\n\n          5. History of acute myocardial infarction within 6 months prior to screening.\n\n          6. Severe COPD as defined by O2 or steroid dependence.\n\n          7. History of systemic inflammatory or collagen vascular disease.\n\n          8. Active and or treated malignancies within 12 months prior to Visit 1 with the\n             exception of basal cell carcinoma.\n\n          9. Any significant systemic illness(es) or medical condition(s) that could lead to\n             difficulty complying with the protocol; or any concurrent condition(s) which, in the\n             investigator's opinion, would prohibit the subject from completing the study, or\n             would not be in the best interest of the subject.\n\n         10. Estimated glomerular filtration rate (GFR) \u2264 30 mL/min/1.73m\u00b2 as calculated by\n             Modification of Diet in Renal Disease (MDRD) study equation [MDRD = 186 X serum\n             creatinine (mg/dl) 1.154 X years -0.203 X (0.742 if female) X (1.210 if African\n             American)].\n\n         11. Liver function tests (SGOT and/or SGPT) > 2.5 times the upper limit of normal range.\n\n         12. Hb < 10 g/dL.\n\n         13. Use of any investigational drug(s) within 30 days prior to screening.\n\n         14. Previous exposure to alagebrium.\n\n         15. Known seropositivity for HIV or hepatitis C, or presence of hepatitis B surface\n             antigen.\n\n         16. Pregnancy or active breast-feeding.  Urine pregnancy tests will be performed on all\n             women who are not post-menopausal for at least 1 year.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "134", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913301", 
            "org_study_id": "ALT-711-0530"
        }, 
        "intervention": {
            "arm_group_label": "Alagebrium", 
            "intervention_name": "Alagebrium", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 30, 2013", 
        "number_of_arms": "1", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and efficacy of alagebrium in subjects diagnosed with diastolic heart failure.  The primary variable for assessing efficacy will be assessment of exercise tolerance using the Six-minute walk test.", 
            "measure": "Exercise Tolerance", 
            "safety_issue": "Yes", 
            "time_frame": "Change from baseline at  Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cardiovascular Clinical Studies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiovascular Clinical Studies", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013", 
        "why_stopped": "Sponsor lost funding"
    }
}